Advanced Renal Cell Carcinoma
Advertisement
Dr. Machaalani highlights his study that evaluated the association between circulating KIM-1 and mRCC tumor biology.
Dr. McGregor shares the opening of the STRIKE trial, which investigates adding tivo to pembro in the mRCC adjuvant setting.
Dr. McGregor opens up about the expansion cohort of the phase 1 ARC-20 study, which looked at casdatifan plus cabozantinib.
Dr. Chahoud talks about the results of the expansion cohort of the phase 1b STELLAR-002 study.
Dr. Haas provides an update on a 5-year follow-up of KEYNOTE-564 and the survival benefits of adjuvant pembrolizumab for RCC.
Dr. Braun details an integrative analysis of the Checkmate 9ER trial that highlights both circulating and TME biomarkers.
Dr. Zhang gives an update on the PDIGREE trial, including new information on tolerability and treatment response.
High KIM-1 may be a biomarker of poor prognosis in RCC and correlates with specific LOF mutations, transcriptions programs.
Tumor microenvironment and circulating factors studied for potential links to treatment response in aRCC.
Machine learning may be a useful tool in predicting renal cell carcinoma tumor response to nivolumab monotherapy.
Patients with mRCC and primary resistant disease to nivolumab plus ipilimumab have worse survival outcomes.
Drs. Beckermann and Braun reflect on key lessons from the trial, emphasizing the importance of prioritizing driver mutations.
Drs. Beckermann and Braun break down the selection process for neoantigens in the trial for personalized RCC vaccines.
Drs. Beckermann and Braun discuss the latter's Nature publication on a personalized neoantigen vaccine for RCC.
Patients with mRCC on Medicare have better survival rates compared with patients on Medicaid or with no insurance.
The combination therapy provided similar survival rates and toxicity in an older patient population.
Dr. Daniel Joyce gives an overview of his study that examined the use of necrosis as a prognostic indicator for mRCC.
First-line IO + IO therapy is linked to higher costs during the first three months of treatment.
Patients were administered oral belzutifan, 120 mg once daily, in addition to oral cabozantinib, 60 mg once daily.
Dr. Albiges discusses the logistical benefits and considerations of subcutaneous administration of nivolumab for RCC.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.